Short-term management of moderate to severe acute post-operative pain

Active Ingredient: Ketorolac

Indication for Ketorolac

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Ketorolac is indicated for the short-term management of moderate to severe acute post-operative pain.

Ketorolac should only be initiated in hospitals. The maximum duration of treatment is two days.

For this indication, competent medicine agencies globally authorize below treatments:

10 mg initial dose, followed by 10-30 mg every 4-6 h, up to a maximum dose of 90 mg/day, for up to 2 days

For:

Dosage regimens

Intramuscular, 10 milligrams ketorolac, one dose. Afterwards, intramuscular, between 10 milligrams ketorolac and 30 milligrams ketorolac, once every 4 to 6 hours, over the duration of up to 2 days.

Detailed description

Adults

The recommended initial dose of ketorolac is 10 mg, followed by 10 to 30 mg every four to six hours as required. In the initial post-operative period, ketorolac may be given as often as every two hours if needed. The lowest effective dose should be given. A total daily dose of 90 mg for non-elderly and 60 mg for the elderly, renally-impaired patients and patients less than 50 kg should not be exceeded. The maximum duration of treatment should not exceed two days.

Reduce dosage in patients under 50 kg.

Opioid analgesics (e.g. morphine, pethidine) may be used concomitantly, and may be required for optimal analgesic effect in the early post-operative period when pain is most severe. Ketorolac does not interfere with opioid binding and does not exacerbate opioid-related respiratory depression or sedation. When used in association with ketorolac IM/IV, the daily dose of opioid is usually less than that normally required. However, opioid side-effects should still be considered, especially in day-case surgery.

Elderly

The elderly are at increased risk of the serious consequences of adverse reactions. If an NSAID is considered necessary, the lowest effective dose should be used and for the shortest possible duration. The patient should be monitored regularly for GI bleeding during NSAID therapy. A total daily dose of 60 mg should not be exceeded.

10 mg initial dose, followed by 10-30 mg every 4-6 h, for up to 2 days

For:

Dosage regimens

Intravenous, 10 milligrams ketorolac, one dose. Afterwards, intravenous, between 10 milligrams ketorolac and 30 milligrams ketorolac, once every 4 to 6 hours, over the duration of up to 2 days.

Detailed description

Adults

The recommended initial dose of ketorolac is 10 mg, followed by 10 to 30 mg every four to six hours as required. In the initial post-operative period, ketorolac may be given as often as every two hours if needed. The lowest effective dose should be given. A total daily dose of 90 mg for non-elderly and 60 mg for the elderly, renally-impaired patients and patients less than 50 kg should not be exceeded. The maximum duration of treatment should not exceed two days.

Reduce dosage in patients under 50 kg.

Opioid analgesics (e.g. morphine, pethidine) may be used concomitantly, and may be required for optimal analgesic effect in the early post-operative period when pain is most severe. Ketorolac does not interfere with opioid binding and does not exacerbate opioid-related respiratory depression or sedation. When used in association with ketorolac IM/IV, the daily dose of opioid is usually less than that normally required. However, opioid side-effects should still be considered, especially in day-case surgery.

Elderly

The elderly are at increased risk of the serious consequences of adverse reactions. If an NSAID is considered necessary, the lowest effective dose should be used and for the shortest possible duration. The patient should be monitored regularly for GI bleeding during NSAID therapy. A total daily dose of 60 mg should not be exceeded.

Active ingredient

Ketorolac

Ketorolac is a non-steroidal anti-inflammatory agent demonstrating analgesic and anti-inflammatory activity. Ketorolac inhibits the cyclo-oxygenase enzyme essential for biosynthesis of prostaglandins. Ketorolac has been shown to reduce prostaglandin levels in the aqueous humour after topical ophthalmic administration.

Read more about Ketorolac

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.

⇈